Swiftly following its first approval in the US, Amgen/Novartis' Aimovig has just been given a CHMP go-ahead in the EU positioning it to be the first CGRP targeting agent on the market there. Launch tactics look set to mirror those in the US.
Novartis AG looks set to capitalize on its first-mover status for its migraine therapy Aimovig following its green light for its EU approval with a launch strategy similar to that being employed in the US.
The EU's Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval for Aimovig...
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
